Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Neuraminidase assays.

M Aymard¹, O Ferraris, L Gerentes

¹National Influenza Centre, Laboratory of Virology, Lyon, France. aymard@rockefeller.univ-lyon1.fr

Developments in Biologicals

|April 20, 2004

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A novel synthetic reversible inhibitor of sialidase efficiently blocks secondary but not primary influenza virus infection of MDCK cells in culture.

Archives of virology·2017

Same author

Evaluation of Crimean-Congo hemorrhagic fever virus in vitro inhibition by chloroquine and chlorpromazine, two FDA approved molecules.

Antiviral research·2015

Same author

[An atypical necrotic wound].

Medecine et maladies infectieuses·2015

Same author

Metabolite fingerprinting of barley whole seeds, endosperms, and embryos during industrial malting.

Journal of biotechnology·2012

Same author

Hybridoma growth in a new generation hollow fibre bioreactor: antibody productivity and consistency.

Cytotechnology·2012

Same author

Report from the Committee on Medical Analysis Laboratories.

Bulletin de l'Academie de medecine·2010

Same journal

Review of Ebola virus infections in domestic animals.

Developments in biologicals·2013

Same journal

Ebola: facing a new transboundary animal disease?

Developments in biologicals·2013

Same journal

Opportunities in diagnostic and vaccine approaches to mitigate potential heartwater spreading and impact on the American mainland.

Developments in biologicals·2013

Same journal

Q fever diagnosis and control in domestic ruminants.

Developments in biologicals·2013

Same journal

Schmallenberg virus.

Developments in biologicals·2013

Same journal

Classical swine fever.

Developments in biologicals·2013

See all related articles

Anti-neuraminidase (NA) antibodies enhance influenza vaccine protection. Standardizing NA content requires addressing antigenic characterization, protein lability, and antibody response measurement challenges for improved vaccine efficacy.

Area of Science:

Virology
Immunology
Vaccinology

Background:

Anti-neuraminidase (NA) antibodies contribute to protective immunity against influenza, particularly when combined with anti-hemagglutinin (HA) antibodies.
Standardizing vaccine NA content is crucial for improving vaccine efficacy and consistency.

Purpose of the Study:

To address key questions regarding the control and measurement of NA content in influenza vaccines.
To evaluate methods for antigenic characterization, protein quantification, and antibody response assessment related to NA.

Main Methods:

Antigenic characterization via enzymatic activity inhibition using fetuin substrate and ferret antisera.
NA protein quantification using ELISA capture assays and assessment of protein lability.
Measurement of anti-NA antibody response through neuraminidase inhibition tests, considering steric hindrance and Triton treatment effects.

Related Experiment Videos

Evaluation of fluorescent (MUN) and chemiluminescent (NA-STAR) substrates for NA subtype differentiation.

Main Results:

Challenges exist in NA antigenic characterization, including low enzymatic activity in MDCK-grown viruses and N1 lability.
NA protein lability at 4°C requires careful monitoring during vaccine production and storage.
Neuraminidase inhibition tests are suitable for measuring anti-NA antibody response, with steric hindrance noted in human sera.
While MUN and NA-STAR substrates rapidly differentiate NA subtypes, they are not suitable for titrating protective NA-inhibiting antibodies.

Conclusions:

Standardizing influenza vaccine NA content necessitates overcoming technical challenges in NA characterization and measurement.
Further research is needed to establish correlations between neuraminidase inhibition, neutralization, and protection in human subjects.
Accurate assessment of NA content and immunogenicity is vital for optimizing influenza vaccine design and efficacy.